Delivery Order SPE2DB24D2205-SPE2DB24FDUQH

Award Date 5/23/24
Potential Completion Date 5/24/24
Potential Value $29K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,279.58, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of March 6, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,240.82, is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of March 5, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,756.63 award is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of April 4, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This is a $6,557.34 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of June 21, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,790.24, is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of June 24, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,375.29, is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of March 7, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the...
This is a $5,317.87 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of March 11, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a $8,604.32 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of March 20, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,945.19 firm-fixed-price contract is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used to manage diabetes. The contract has an ultimate completion date of November 6, 2024. This delivery order is placed under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has a ceiling value of $12,837.93 and a completion date of November 17, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB24FDUQH
    Delivery Order

This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $28,599.75, is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of May 24, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 11:58 AM